Cerus Corporation (CERS) has risen sharply, recording gains of 11.84% in the past 4 weeks. However, the stock has corrected -4.25% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 10.7% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 2.43% and the 50-Day Moving Average is 9.47%. Cerus Corporation (NASDAQ:CERS): stock turned positive on Friday. Though the stock opened at $6.89, the bulls momentum made the stock top out at $7.01 level for the day. The stock recorded a low of $6.85 and closed the trading day at $6.99, in the green by 0.87%. The total traded volume for the day was 773,099. The stock had closed at $6.93 in the previous days trading.
The company Insiders own 6.2% of Cerus Corporation shares according to the proxy statements. Institutional Investors own 66.12% of Cerus Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -50.93%.
Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Companys INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries, including the United States, certain countries in Europe, The Commonwealth of Independent States (CIS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.